Back to top

View the PFP Archive

Profit from the Pros

Critical Market Juncture: Absurdity

Cooker here for Matras the rest of the week...

I've been waiting for a day like Wednesday for a few weeks. The "trade war" escalated a bit further, with China retaliating, and the S&P 500 opened 1.5% lower (via SPY). Then it reversed just as quickly because we had finally reached a critical market juncture: absurdity.

That's when the size of the market correction dwarfs the size of the tariffs' impact by nearly an order of magnitude. Indeed, we're talking $2-$4 trillion vs a few hundred billion.

Most calculating investors just want it to be over with so we can focus on something more interesting. Like earnings season. But that doesn't really get rolling for a few more weeks to the point where we have enough corporate results and guidance that we know the outlook remains robust -- or that we should pack up our tents on Mt. Bull.

All Eyes on the Health of Growth

All we have right now are the earnings growth estimates of 16%, 17.9%, 19.1%, and 15.6% for Q1, Q2, Q3, and Q4 respectively (Q4 drops a bit sequentially because it has a much harder "comp" than Q3).

As long as that earnings picture remains intact (or better) -- topped-off by +5.3 growth on the top line -- then I remain a buyer of stocks under 18 times those estimates, or all the way up to S&P 2800. If the picture improves, and we shake off the mid-term election angst, 3,000 here we come.

My favorite areas for this growth are Technology and Healthcare -- the innovation sectors. And I just updated my "cheat sheet" of driving forces that should make every investor develop a long-term strategy for capitalizing on Healthcare innovation and profits...

Healthcare Megatrends for Investors

Kevin Cook

Senior Stock Strategist, Zacks Investment Research

Sponsor

Big Stock Gains from Healthcare Innovations

New treatments are pouring off the pipeline. The needs of an aging population are rapidly increasing.

Insurance companies are demanding alternatives to costly procedures.

Already this year, medical megatrends like these have led Zacks to wins of +155.6%, +119.1%, +75.6%, and +98.1% in as little as 5 weeks.

Moving forward, which stocks have similar breakout potential in the months ahead?

See Zacks' latest picks >>

Most Popular Articles from Zacks.com

Looking Ahead to the Q1 Earnings Season

Earnings growth is expected to be in double-digit territory 11 of the 16 Zacks sectors. Read More »

Top Analyst Reports for Amazon, Visa & BHP Billiton

Research reports which have been hand-picked from the roughly 70 reports published by our analyst team today. Read More »

4 Ways You Can Get Rich Off the Permian Basin's Oil Boom

The Permian Shale, which is spread over roughly 75,000 square miles of western Texas and southeastern New Mexico, is believed to hold enough oil to feed all the domestic refineries for 12 years. Read More »

Avoid Chinese Trade War Concerns with These 3 Retail Stocks

Fashion based retail is one area of the U.S. economy that might be able to stay above the tariff fray. Read More »

Why These Sector ETFs Are Winning Picks Now

These sectors have strong fundamentals underlying and thus offer a nice buy-the-dip opportunity. Read More »

Sponsor

Start Every Day Ahead of Wall Street

Before you make a trade, get today's market news from Zacks' latest Ahead of Wall Street article. With timely information from Zacks' analysts, each daily article features a preview of where the market is headed. Plus, Zacks #1s on the move, stock research reports, earnings and economic news, and a top-headline analyst blog. All of it in one easy-to-follow place to give you the edge.

Get the latest news >>

Bull of the Day: Virtu Financial (VIRT)

This stock is probably happy to see the return of big volatility to the stock market. Read More »

New Zacks Strong Buys for April 5th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today. Read More »

Customize Your Profit from the Pros Delivery
Connect with Us:
Facebook
Twitter
StockTwits
Contact Info:

Phone: 1.800.767.3771 ext. 9339
Email: support@zacks.com